JP MORGAN/CALL/BOSTON SCIENTIFIC/80/0.1/20.06.25 | Market Closed - Börse Stuttgart 06:35:03 2024-06-21 EDT | ||
| 1.1 EUR | +0.92% |
|
| Current month | +4.76% | ||
| 1 month | +2.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 1.1 | +0.92% |
| 24-06-20 | 1.09 | 0.00% |
| 24-06-19 | 1.09 | +1.87% |
| 24-06-18 | 1.07 | -7.76% |
| 24-06-17 | 1.16 | +3.57% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 06:35 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK2LLA |
| ISIN | DE000JK2LLA6 |
| Date issued | 2024-02-29 |
| Strike | 80 $ |
| Maturity | 2025-06-20 (363 Days) |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.2 € |
|---|---|
| Lowest since issue | 0.67 € |
| Spread | 0.06 € |
| Spread % | 4.92% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
77.71
USD
Average target price
82.35
USD
Spread / Average Target
+5.98%
- Stock Market
- Warrants
- Warrant
